UY40173A - Composiciones que comprenden aticaprant - Google Patents

Composiciones que comprenden aticaprant

Info

Publication number
UY40173A
UY40173A UY0001040173A UY40173A UY40173A UY 40173 A UY40173 A UY 40173A UY 0001040173 A UY0001040173 A UY 0001040173A UY 40173 A UY40173 A UY 40173A UY 40173 A UY40173 A UY 40173A
Authority
UY
Uruguay
Prior art keywords
compositions
aticaprant
methods
description relates
tablet form
Prior art date
Application number
UY0001040173A
Other languages
English (en)
Spanish (es)
Inventor
Mark Schmidt
Vanina Popova
Adam Savitz
Rama Melkote
C Drevets Wayne
Srihari Gopal
Darrell Pemberton
Chakradhar Lagishetty
Iva Kezic
Martha Felix Goyvaerts Nicolaas
N Samtani Mahesh
Tom Huybrechts
Van Der Avoort Geert
Matthieu Ravelingien
Martinez Marcos Laura
Tatiana Marcozzi
Katarina Jokicevic
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of UY40173A publication Critical patent/UY40173A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY0001040173A 2022-03-07 2023-03-06 Composiciones que comprenden aticaprant UY40173A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263317471P 2022-03-07 2022-03-07

Publications (1)

Publication Number Publication Date
UY40173A true UY40173A (es) 2023-09-29

Family

ID=85980700

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001040173A UY40173A (es) 2022-03-07 2023-03-06 Composiciones que comprenden aticaprant

Country Status (16)

Country Link
US (3) US20230277500A1 (cg-RX-API-DMAC10.html)
EP (2) EP4748441A3 (cg-RX-API-DMAC10.html)
JP (1) JP2025508069A (cg-RX-API-DMAC10.html)
KR (1) KR20240152410A (cg-RX-API-DMAC10.html)
CN (1) CN119156202A (cg-RX-API-DMAC10.html)
AU (1) AU2023231767A1 (cg-RX-API-DMAC10.html)
CA (1) CA3254546A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024002648A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024012454A2 (cg-RX-API-DMAC10.html)
ES (1) ES3064226T3 (cg-RX-API-DMAC10.html)
IL (1) IL315415A (cg-RX-API-DMAC10.html)
JO (1) JOP20240196A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024010977A (cg-RX-API-DMAC10.html)
TW (1) TW202400135A (cg-RX-API-DMAC10.html)
UY (1) UY40173A (cg-RX-API-DMAC10.html)
WO (1) WO2023170554A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN117615757A (zh) * 2021-05-04 2024-02-27 杨森制药公司 用于治疗抑郁症的组合物和方法
CA3254546A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. COMPOSITIONS CONTAINING ATICAPRANT
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
ES2189759T3 (es) 1999-05-12 2003-07-16 Hoffmann La Roche Derivados de imidazoiacepina.
US20020052365A1 (en) 2000-10-05 2002-05-02 Mohler Hanns Selective anxiolytic therapeutic agents
JP2004518654A (ja) 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
WO2003082832A2 (en) 2002-03-28 2003-10-09 Wisys Technology Foundation, Inc. Anxiolytic agents with reduced sedative and ataxic effects
PT2208727E (pt) 2002-09-19 2012-10-11 Lilly Co Eli Éteres diarílicos como antagonista do receptor opióide
EP1606275B1 (en) 2003-03-07 2008-08-27 Eli Lilly And Company Opioid receptor antagonists
WO2004080968A1 (en) 2003-03-07 2004-09-23 Eli Lilly And Company 6-substituted nicotinamide derivatives as opioid receptor antagonists
CN1890208A (zh) 2003-12-12 2007-01-03 伊莱利利公司 类鸦片受体拮抗剂
BRPI0417714A (pt) 2003-12-22 2007-03-20 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
JP2007528898A (ja) 2004-03-12 2007-10-18 イーライ リリー アンド カンパニー オピオイド受容体拮抗物質
AU2005222640A1 (en) 2004-03-12 2005-09-29 The Mclean Hospital Corporation Salvinorin derivatives and uses thereof
US7381750B2 (en) 2004-03-12 2008-06-03 Eli Lilly And Company Amino-phenoxymethyl-benzamide opioid receptor antagonists
US7378448B2 (en) 2004-03-15 2008-05-27 Eli Lilly And Company Diphenylether amide derivatives as opioid receptor antagonists
WO2005090303A1 (en) 2004-03-15 2005-09-29 Eli Lilly And Company 4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
US8551986B2 (en) 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
PL2001456T3 (pl) 2006-04-04 2010-05-31 Emodys Gmbh Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych
US8633175B2 (en) 2006-08-09 2014-01-21 Glaxosmithkline Llc Compounds as antagonists or inverse agonists at opioid receptors
JP2010500372A (ja) 2006-08-09 2010-01-07 スミスクライン ビーチャム コーポレーション オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物
MX2009002527A (es) 2006-09-08 2009-03-20 Pfizer Prod Inc Derivados de eter diarilico y usos de los mismos.
US7709522B2 (en) 2008-01-22 2010-05-04 Eli Lilly And Company Kappa selective opioid receptor antagonist
EP3566697B1 (en) * 2009-11-09 2024-09-11 Wyeth LLC Tablet formulations of neratinib maleate
US20130303497A1 (en) 2010-08-05 2013-11-14 Conrig Pharma Aps Deuterated 5-ht1a receptor agonists
WO2013086496A2 (en) 2011-12-09 2013-06-13 Research Triangle Institute 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists
CA2933733A1 (en) 2013-12-20 2015-06-25 Connie Sanchez Morillo Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
US10377698B2 (en) 2015-03-30 2019-08-13 University Of Innsbruck Diphenethylamine derivatives which are inter alia useful as analgesics and method for their production
WO2016191763A2 (en) 2015-05-28 2016-12-01 Georgetown University Use of methadone metabolites for treatment of anxiety and depression
TWI804919B (zh) * 2015-06-30 2023-06-11 美商建南德克公司 含藥物之立即釋放錠劑及形成該錠劑的方法
EP3468540A4 (en) 2016-06-13 2020-03-18 Board Of Regents Of the University Of Texas System PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING PAIN
EP3490542A4 (en) 2016-07-26 2020-07-08 Flagship Pioneering Innovations V, Inc. NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE
AU2017325870B2 (en) 2016-09-16 2021-07-22 Research Traingle Institute Tetrahydroisoquinoline kappa opioid antagonists
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
DK3596069T3 (da) 2017-03-17 2022-08-01 Scripps Research Inst Kappa-opioid-receptor-antagonister og produkter og fremgangsmåder relateret dertil
SG10201802129QA (en) * 2017-07-05 2019-02-27 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US20190255036A1 (en) 2018-02-16 2019-08-22 Alexander Kariman Compound and method for reducing neuropathic pain and depression
US11820835B2 (en) 2018-03-23 2023-11-21 University Of Kansas Cyclic tetrapeptide analogs
US11491144B2 (en) 2018-03-30 2022-11-08 The Florida State University Research Foundation, Incorporated Methods of treating fragile X mental retardation syndrome
US11103171B2 (en) 2018-10-23 2021-08-31 BlackThor Therapeutics, Ine. Systems and methods for screening, diagnosing, and stratifying patients
US20200171025A1 (en) * 2018-11-29 2020-06-04 Srinivasa Rao Parella Pharmaceutical composition comprising brexpiprazole and process for preparation thereof
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN114195693A (zh) 2020-09-17 2022-03-18 广东东阳光药业有限公司 一种酰胺化合物的晶型及其制备方法
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
WO2022234457A1 (en) * 2021-05-04 2022-11-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CA3254546A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. COMPOSITIONS CONTAINING ATICAPRANT
EP4489748A1 (en) 2022-03-07 2025-01-15 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰

Also Published As

Publication number Publication date
JP2025508069A (ja) 2025-03-21
JOP20240196A1 (ar) 2024-09-05
CL2024002648A1 (es) 2025-01-24
CA3254546A1 (en) 2023-09-14
CN119156202A (zh) 2024-12-17
IL315415A (en) 2024-11-01
TW202400135A (zh) 2024-01-01
US20240269110A1 (en) 2024-08-15
WO2023170554A1 (en) 2023-09-14
CO2024012454A2 (es) 2024-09-30
US20230277500A1 (en) 2023-09-07
US20250228819A1 (en) 2025-07-17
ES3064226T3 (en) 2026-04-23
EP4489730B1 (en) 2026-01-21
MX2024010977A (es) 2024-12-06
US12201610B2 (en) 2025-01-21
EP4489730C0 (en) 2026-01-21
EP4748441A2 (en) 2026-05-27
AU2023231767A1 (en) 2024-10-24
EP4748441A3 (en) 2026-06-17
EP4489730A1 (en) 2025-01-15
KR20240152410A (ko) 2024-10-21

Similar Documents

Publication Publication Date Title
MX2024010977A (es) Composiciones que comprenden aticaprant
CO2019009258A2 (es) Administración rápida y controlada de composiciones con efectos séquito restaurados
CL2020002841A1 (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
MX338535B (es) Inhibidores de ibat para el tratamiento de enfermeades hepaticas.
MX2020003605A (es) Manipulación del metabolismo de triptamina.
PT3852525T (pt) Método para obter uma população enriquecida de células estaminais mesenquimais funcionais, células obtidas a partir do mesmo e composições compreendendo as mesmas
MX2018007871A (es) Composiciones para el cuidado personal.
CR11744A (es) Formulacion liquida para deferiprona con gusto agradable al paladar
CO2020014515A2 (es) Anticuerpos anti-tmeff2 monoespecíficos y multiespecíficos y sus usos
MX2019015868A (es) Nueva psicosa-6-fosfato fosfatasa, composición para producir psicosa que incluye dicha enzima, método para producir psicosa usando dicha enzima.
AR050717A1 (es) Composiciones farmaceuticas
CR20150282A (es) Método para sincronización del tiempo de inseminación en cerdas jóvenes
MX381237B (es) Composiciones edulcorantes que contienen rebaudiósidos d.
CO2022005952A2 (es) Extracto de algas concentrado
CR11078A (es) Una composicion de liberacion prolongada que comprende un derivado de somatostatina en microparticulas
CO6300935A2 (es) Formulaciones orales e inyectables de compuestos de tetraciclina
MX2016015961A (es) Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas.
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2019008460A (es) Metodos para tratar esclerosis multiple usando celulas t autologas.
MX2013013393A (es) Composiciones de cuidado oral.
CO2018013828A2 (es) Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato
AR110808A1 (es) Estilbenos naturales como edulcorantes o mejoradores del dulzor
ECSP19091293A (es) Nuevas formulaciones orales de belinostat
AR076520A1 (es) Parasiticidas sanguineos. composicion